☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
PHASE 3 TRIALS
Regeneron's Dupixent (Dupilumab) Achieves 1EP & 2EP in two P-III trial for Inadequately-Controlled Chronic Rhinosinusitis with...
October 16, 2018
Pfizer and Astellas Amends Clinical Research Protocols of Xtandi for 2 Phase III to treat Hormone-Sensitive Prostate Cancer (HSPC)
August 23, 2018
Load more...
Back to Home